ATE269081T1 - Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen - Google Patents

Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen

Info

Publication number
ATE269081T1
ATE269081T1 AT00962131T AT00962131T ATE269081T1 AT E269081 T1 ATE269081 T1 AT E269081T1 AT 00962131 T AT00962131 T AT 00962131T AT 00962131 T AT00962131 T AT 00962131T AT E269081 T1 ATE269081 T1 AT E269081T1
Authority
AT
Austria
Prior art keywords
viral infections
prevention
treatment
nucleoside analogues
dioxolane nucleoside
Prior art date
Application number
AT00962131T
Other languages
English (en)
Inventor
Francis Giles
Jean Bedard
Robert Rando
Original Assignee
Shire Biochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Biochem Inc filed Critical Shire Biochem Inc
Application granted granted Critical
Publication of ATE269081T1 publication Critical patent/ATE269081T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT00962131T 1999-09-24 2000-09-22 Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen ATE269081T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15570599P 1999-09-24 1999-09-24
US15570499P 1999-09-24 1999-09-24
PCT/CA2000/001094 WO2001022950A2 (en) 1999-09-24 2000-09-22 Diosolane nucleoside analogs for the treatment or prevention of viral infection

Publications (1)

Publication Number Publication Date
ATE269081T1 true ATE269081T1 (de) 2004-07-15

Family

ID=26852544

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00962131T ATE269081T1 (de) 1999-09-24 2000-09-22 Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen

Country Status (9)

Country Link
US (2) US6583149B1 (de)
EP (1) EP1214074B1 (de)
JP (1) JP2003510271A (de)
AT (1) ATE269081T1 (de)
AU (1) AU777869B2 (de)
CA (1) CA2385349A1 (de)
DE (1) DE60011637T2 (de)
ES (1) ES2218216T3 (de)
WO (1) WO2001022950A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8372851B2 (en) * 2005-10-21 2013-02-12 Exelixis, Inc. Pyrazolo pyrimidines as casein kinase II (CK2) modulators
US8171550B2 (en) * 2006-08-07 2012-05-01 Webroot Inc. System and method for defining and detecting pestware with function parameters
JP5330375B2 (ja) * 2007-04-25 2013-10-30 エグゼリクシス， インコーポレイテッド カゼインキナーゼｉｉ（ｃｋ２）モジュレーターとしてのピリミジノン類
ES2572631T3 (es) 2008-01-25 2016-06-01 Chimerix, Inc. Métodos de tratamiento de infecciones virales
CA2770282A1 (en) 2009-08-03 2011-02-10 Chimerix, Inc. Composition and methods of treating viral infections and viral induced tumors
EP3578563B1 (de) 2011-12-22 2021-04-14 Geron Corporation Guanin-analoga als telomerasesubstrate und telomerlängenaffektoren
CN103288806A (zh) * 2013-07-02 2013-09-11 山东大学 一种曲沙他滨的合成方法
CN106138018B (zh) 2015-04-02 2020-03-13 广州洁成生物科技有限公司 羟基二苯甲酮在制备抗病毒和抗肿瘤药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5728575A (en) 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
US5817667A (en) 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
EP0584347B1 (de) 1992-03-04 2003-01-15 Cell Therapeutics, Inc. Enantiomere hydroxylierte xanthinverbindungen
GB9226879D0 (en) * 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
CA2171550C (en) * 1993-09-10 2008-08-26 Raymond F. Schinazi Nucleosides with anti-hepatitis b virus activity
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
GB9525606D0 (en) 1995-12-14 1996-02-14 Iaf Biochem Int Method and compositions for the synthesis of dioxolane nucleosides with › - configuration
SE506039C2 (sv) 1996-02-29 1997-11-03 Tetra Laval Holdings & Finance Homogeniseringsventil
US5792773A (en) 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
US5792733A (en) * 1997-08-14 1998-08-11 The Lubrizol Corporation Antiwear compositions containing phosphorus compounds and olefins
CA2362570A1 (en) 1999-02-11 2000-08-17 Shire Biochem Inc. Stereoselective synthesis of nucleoside analogues
WO2000057861A2 (en) 1999-03-29 2000-10-05 Shire Biochem Inc. Use of cytidine derivatives for the treatment of leukaemia
US6653318B1 (en) * 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use

Also Published As

Publication number Publication date
US6964968B2 (en) 2005-11-15
JP2003510271A (ja) 2003-03-18
US6583149B1 (en) 2003-06-24
ES2218216T3 (es) 2004-11-16
AU777869B2 (en) 2004-11-04
EP1214074B1 (de) 2004-06-16
WO2001022950A3 (en) 2001-10-25
US20040014757A1 (en) 2004-01-22
WO2001022950A2 (en) 2001-04-05
DE60011637T2 (de) 2004-11-11
EP1214074A2 (de) 2002-06-19
AU7399000A (en) 2001-04-30
DE60011637D1 (de) 2004-07-22
CA2385349A1 (en) 2001-04-05

Similar Documents

Publication Publication Date Title
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
WO2001060315A3 (en) Method for the treatment or prevention of flavivirus infections using nucleoside analogues
WO2001032153A3 (en) Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
BR9815166A (pt) "método de inibição da replicação de vìrus, composto, método de inibição da replicação de citomegalovìrus, composto antiviral, utilização de um composto, composição farmacêutica, composição farmacêutica inibidora da replicação de vìrus e de citomegalovìrus e composição farmacêutica antiviral"
EA200800932A1 (ru) Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
WO2003026589A3 (en) Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
DK0666749T3 (da) Enantiomert rene beta-D-dioxalannukleosider med selektiv antihepatitis B virus aktivitet
WO2003063771A3 (en) N4-acylcytosine nucleosides for treatment of viral iinfections
PE20080179A1 (es) FORMAS CRISTALINAS DE LA SAL MALEATO DE 5-AMINO-3-(2',3'-DI-O-ACETIL-BETA-D-RIBOFURANOSIL)-3H-TIAZOLO[4,5-d]PIRIMIDIN-2-ONA
ES541103A0 (es) Procedimiento de obtencion de una composicion para el trata-miento de infecciones virales
ATE512973T1 (de) Nukleosid-arylphosphoramidate und ihre verwendung als antivirale mittel zur behandlung von hepatitis-c-virus
BR9909474A (pt) Formas ii, cristalina e v de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, solvato de etanol de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, composição, composto, uso de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, e, processos para o tratamento de uma infecção viral em um humano e para a produção de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol
EP0270317A3 (de) Pharmaceutische Zuberatung zur Behandlung von Virus-Krankheiten
WO2010068708A3 (en) 3'-azido purine nucleotide prodrugs for treatment of viral infections
ATE269081T1 (de) Dioxolan nukleosidanalogen zur behandlung und vorbeugung von viralen infektionen
WO2000053167A3 (en) Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
BR0107912A (pt) Composto, composições, e, métodos para tratar ou prevenir o c ncer ou doença neoplástica, método para inibir o desenvolvimento de uma célula cancerìgena ou célula neoplástica, método para tratar ou prevenir uma infecção viral em um paciente, e para inibir a replicação ou a infectividade de um vìrus
KR910000734A (ko) 네플라노신 유도체
EP0956021A4 (de) Beta-l-dioxolanuridin-analoge und verfahren zur behandlung und vorbeugung von viralen infektionen
BRPI0508079A (pt) composto ou uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos de tratar ou prevenir uma infecção viral com hepatite c em um mamìfero e de inibir replicação de um vìrus da hepatite c
AU551678B2 (en) Antiviral alpha alpha dialkyl adamantylethylamines
EP0286825A3 (de) Verwendung von 3'-fluro-3'-deoxythymidine zur Herstellung von medicamenten zur Behandlung von Viruskrankheiten
DK0500953T3 (da) Potentiator af antineoplastisk virkning og antineoplastisk middel
WO2023154905A8 (en) Antiviral naphthyridinone compounds
JP2002531495A5 (de)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties